Effect of repeated four-monthly albendazole treatments on malaria in pre-school children living in communities endemic for Ascaris lumbricoides: a double-blind placebo-controlled randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44215995

Enrollment

1055

Registered

2008-09-25

Start date

2006-05-16

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria, helminth parasitisation Infections and Infestations Falciparum malaria

Interventions

There were two groups: the treatment (albendazole) group and the placebo group. A dose of 200 mg (one tablet) of albendazole was given to children aged 1 year. A dose of 400 mg (two tablets) of albend

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pre-school children aged 12 - 59 months, either sex

Exclusion criteria

Exclusion criteria: 1. Severe anaemia less than 5 g/dl 2. Severe malaria

Design outcomes

Primary

Measure	Time frame
1. Incidence of malaria, measured at baseline and 4, 8, 12 and 14 months 2. Malaria attacks, measured at baseline and 4, 8, 12 and 14 months 3. Infection with soil-transmitted helminths, measured at baseline and 4, 8, 12 and 14 months	—

Secondary

Measure	Time frame
1. Nutritional status, measured at baseline and 14 months 2. Haemoglobin, measured at baseline and 4, 8, 12 and 14 months	—

Countries

Nigeria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 30, 2026